Downstream formulation of a multicomponent veterinary herbal extract requires marker-based dosing rather than single-molecule purity adjustment. The product is incorporated only after Karl Fischer water correction, with the dried extract weight adjusted against the supplier’s batch certificate. The following application tracks reflect the dosage forms listed in the API specification; each track is separated by a step-change in unit operation rather than by therapeutic claim. Because published data for this specific extract is limited in peer-reviewed form, the process windows below are drawn from analogous dried herbal extracts with similar hygroscopicity and particle-size reduction behaviour.

Batch-level addition to swine nursery and grower feed is executed through a sequential dilution procedure that begins with a 1:10 preblend of the API in ground maize or lactose monohydrate. The preblend is screened through a 710 µm stainless steel mesh before metering into a 500–1,000 kg twin-shaft paddle mixer operating at 22–28 rpm for 12–15 min; at a final inclusion set between 0.5 kg/tonne and 2.0 kg/tonne of finished feed, the coefficient of variation for the marker compound is maintained below 5.0 % across ten sampling points when post-mixer sampling follows the first 8–10 revolutions after discharge begins. Carry-over control under Regulation (EU) 2019/4 and feed hygiene obligations under Regulation (EC) No 183/2005 Annex II require validated flush cycles of 2–5 % w/w of mixer capacity using ground maize, with subsequent quantification of the marker compound in the flush material by HPLC-UV. Downstream pelleting through a conditioner at 70–85 °C for 20–40 s and a 3–4 mm die is permissible only when the applicant has confirmed marker recovery of at least 90 % after thermal processing; if the marker is heat-labile, post-pelleting liquid spray application is the permitted alternative, though that route may require a reduced dry premix addition ratio and separate stability data. Terminal product types include pelleted creep feed, crumble feed, and meal-type complete feed for swine; in food-producing species, the withdrawal period stated in the marketing authorization is binding and is not modified by changing the addition ratio.

What governs reconstitution stability in drinking-water soluble powders?

Water medication lines in poultry houses operate under variable pH, dissolved ion load, and chlorine residual, so the soluble powder formula is built around a carrier system rather than raw API dispersion. The API is dry-mixed at 10–25 % w/w with lactose monohydrate and citric acid buffer in a double-cone blender for 20 min at 12–15 rpm, then vacuum-packed in aluminium foil sachets. At field dilution of 1 g/L to 2 g/L in drinking water, the resulting pH is held between 5.5 and 7.0; water with total hardness above 300 mg/L as CaCO₃ or pH above 8.0 reduces solution clarity and may precipitate polyphenolic fractions. Under those conditions, a 0.2 % w/w citric acid buffer adjustment is validated before the stock solution is diluted into the medicator. Compliance for this dosage form falls under Regulation (EU) 2019/6 for veterinary medicinal products, with residual solvent testing according to VICH GL18 and dissolution-style reconstitution checks based on Ph. Eur. 2.9.3. Production of the finished soluble powder is performed in a ISO 14644-1 Class 8 zone with controlled relative humidity below 40 %; sachet fill weight is checked every 15 min on an in-line check weigher. Terminal product types include 100 g, 500 g, and 1 kg water-soluble sachets for broilers, layers, and turkeys. Storage above 30 °C or exposure to chlorine residuals above 2 ppm is not recommended because both conditions accelerate marker oxidation and reduce reconstitution reliability.

Injectable Solutions Require Endotoxin Control and Heat-Labile Marker Assays

Injectable dosage forms are manufactured only after the dried extract is dissolved in Water for Injection at 40 ± 2 °C under continuous agitation for 30–45 min. The final API concentration is adjusted to 1.0–5.0 % w/v of dried extract, with the exact loading fixed by the target marker dose and the batch assay value; a representative configuration uses a 2.0 % w/v dried extract concentration after correction for water content. The solution is cooled to 20–25 °C, adjusted to pH 5.0–6.5 with 0.1 N hydrochloric acid or sodium hydroxide, and filtered through a 0.22 µm polyethersulfone membrane. Sterile filtration should be preceded by a porosity test, because polyphenolic and polysaccharide fractions in herbal extracts may increase filter load and reduce throughput below 40 L/m² at 1.0 bar differential pressure. Filling into amber glass vials is performed under ISO 14644-1 Class A conditions within a Class B background, consistent with EU GMP Annex 1. Endotoxin testing according to Ph. Eur. 2.6.14 or USP <85> is required on each batch; a typical acceptance limit for a parenteral product of this category is ≤ 0.5 EU/mL, but the final limit must be derived from the maximum dose and the target species. Published data for heat-stable marker recovery in this specific extract is limited, so terminal sterilisation by autoclaving at 121 °C for 15 min should not replace sterile filtration unless the applicant submits spiked thermal-degradation data showing marker recovery of at least 90 %. Residual solvent and impurity profiling follows VICH GL18(R2). Terminal product types include 10 mL, 50 mL, and 100 mL vials for intramuscular or subcutaneous administration in cattle and swine; the formulation is not suitable for intravenous use unless pyrogenicity and osmolality data are filed separately.

Direct compression is evaluated only after the API has been milled to a particle-size distribution with D90 ≤ 150 µm and pre-dried at 40 °C until loss on drying is ≤ 3.0 % w/w. When the tablet core is formulated at 10–25 % w/w API, a representative 600 mg core contains 60–150 mg of dried extract, with the exact amount corrected for marker assay and water content. The blend is prepared by screening the API through a 40-mesh stainless steel sieve, loading it into a V-blender with microcrystalline cellulose and croscarmellose sodium, and mixing for 20 min at 25 rpm; magnesium stearate at 0.5 % w/w is added in the final 3 min to limit over-lubrication. Compression is run on a rotary tablet press with 6–10 kp hardness and friability below 0.8 % after 100 rotations, while weight variation is controlled under USP <905> and Ph. Eur. 2.9.40. Dissolution acceptance is set provisionally at Q=75 % in 45 min using USP <711> apparatus II at 50 rpm in 0.1 N hydrochloric acid; if the formulation is enteric-coated, the acid-stage exposure and buffer-stage dissolution profile are validated separately. Compression room relative humidity above 60 % causes picking and sticking on the punch faces, so dehumidified air at 35–45 % RH is required. Terminal product types include 100 mg, 200 mg, and 500 mg scored tablets for companion animals and calves; split-tablet content uniformity is not assumed and must be confirmed for scored configurations.

When Low-Dust Granules Are Required for Premix Uniformity

Fluid-bed granulation is selected when the API must be converted into a low-dust granule to prevent segregation in subsequent feed premix blending. The dry API is loaded at 5–20 % w/w of the final granule mass, blended with lactose monohydrate and pregelatinised starch, and sprayed with a 3–5 % w/w aqueous polyvinylpyrrolidone K30 binder solution. Top-spray processing is performed with an inlet air temperature of 65 ± 3 °C, product bed temperature of 35–40 °C, and spray rate of 10–15 g/min/kg of dry charge; final loss on drying is targeted at 2–4 % w/w. Particle-size distribution is checked by sieve analysis according to Ph. Eur. 2.9.12, with the target granule fraction retained between 250 µm and 425 µm at not less than 70 % w/w. Oversize granules above 850 µm are milled and rescreened, while fines below 150 µm are recycled into the next batch at a rate not exceeding 15 % of the new dry charge to avoid particle-size drift. Because the granule is ultimately dispersed in feed, carry-over limits under Regulation (EU) 2019/4 apply and the granule blend is sampled at five points after 10 min of ribbon mixing. Terminal product types include 1 kg and 5 kg low-dust premix granules for oral dosing via feed or for further dilution in swine and ruminant rations. Published data for the compaction and granulation endpoint of this specific extract is limited; the moisture end-point should be validated by batch-spiking studies rather than transferred directly from single-component herbal extracts.

Hard Gelatin Capsule Filling and Moisture Exchange in Two-Piece Shells

Capsule filling with hygroscopic multicomponent extracts is controlled primarily by moisture exchange between the fill and the hard gelatin shell. The API is pre-dried to loss on drying ≤ 3.0 % w/w and sized through a 60-mesh sieve before blending with lactose monohydrate or tapioca dextrin at 15–30 % w/w of the final fill weight. A representative size 1 capsule with a 250 mg fill weight contains 37.5–75 mg of dried extract, adjusted for marker content. Filling is performed under controlled relative humidity ≤ 40 %, and the empty shell moisture is maintained at ≤ 4.0 % w/w measured by USP <921> Karl Fischer titration, because lower shell moisture reduces brittleness without inducing shrink-back. Weight variation is monitored under USP <905> and Ph. Eur. 2.9.40 every 15 min during encapsulation; dissolution is assessed with USP <711> apparatus I at 100 rpm in 900 mL of 0.1 N hydrochloric acid. Terminal product types include 100 mg and 250 mg hard gelatin capsules for non-food companion animals; the formulation is not intended for food-producing species unless residue depletion data are available. Storage with a silica gel desiccant is required when the packed product is exposed to tropical humidity above 70 % RH, and the desiccant quantity is calculated from the moisture vapour transmission rate of the primary container rather than fixed at a single unit count.